The BRCA1-like classifier showed clinical validity and utility to predict the benefit of intensified platinum-based chemotherapy for stage III HER2-negative breast cancer patients [15, 28–30] and for stage III TNBC patients [15]. Here, ERBB2 is linked to breast carcinoma.